Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 2,690 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Normal saline solution Clear all

Conditions: Thalassemia, Sickle Cell Disease, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic-granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Schwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Fanconi Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia
Interventions: Alefacept; Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 21 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Critical Illness, Acute Kidney Injury
Interventions: 0.9% Saline, Physiologically-balanced isotonic crystalloid; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 5,381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Osteoarthritis
Interventions: Dextrose Prolotherapy, Saline Prolotherapy, At-home physical therapy exercise group; Procedure · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 40 Years to 70 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: SARS-CoV-2
Interventions: mRNA-1273.214, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 2 Months to 6 Months
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 39
States / cities: Bessemer, Alabama • Birmingham, Alabama • Tucson, Arizona + 34 more

Conditions: Hemorrhage, Surgical, Tonsillar Bleeding
Interventions: Tranexamic Acid Injectable Product, Normal Saline; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 2 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Davis, California • Providence, Rhode Island • San Antonio, Texas

Conditions: Pain
Interventions: Ketamine IV Infusion, Ketamine IV push; Drug
Lead sponsor: Alameda Health System; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Oakland, California

Conditions: Diseases, Metabolic, Insulin Sensitivity
Interventions: Intralipid, ClinOleic, Dextrose, Saline (control); Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cytomegalovirus Infections
Interventions: CMV gB vaccine, MF59 adjuvant, Placebo; Biological · Drug
Lead sponsor: Robert Pass, MD; Other
Eligibility: 14 Years to 40 Years · Female only
Enrollment: 464 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2010
U.S. locations: 2
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama

Conditions: Migraine Headache
Interventions: bupivicaine, normal saline, methylprednisolone, lidocaine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy Participants, Non-cystic Fibrosis Bronchiectasis
Interventions: Rev-56 for Inhalation, Placebo: Normal saline; Combination Product · Drug
Lead sponsor: Revagenix, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Sinusitis, Nasal Polyps
Interventions: Verapamil Hydrochloride Intranasal; Drug
Lead sponsor: Benjamin Bleier; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glenohumeral Arthritis, Total Shoulder Arthroplasty
Interventions: Ropivacaine, liposomal bupivacaine; Drug
Lead sponsor: The Christ Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Volunteers
Interventions: NCTX (PEGylated Liposomal Iodixanol Injection), Saline Placebo; Drug
Lead sponsor: Marval Pharma Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, Relapsed, Adult
Interventions: Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO); Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypoglycemia; Iatrogenic
Interventions: Low Fructose, Saline, Somatostatin, Insulin, Glucagon, Dextrose solution, High Fructose; Drug
Lead sponsor: Jason Winnick; Other
Eligibility: 21 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: GZR-18, Placebo; Drug · Other
Lead sponsor: Gan and Lee Pharmaceuticals, USA; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Influenza
Interventions: Influenza A/H7N7 Vaccine, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoarthritis of the Shoulder, Adhesive Capsulitis
Interventions: FX006, Normal Saline; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 27
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more

Conditions: Osteoarthritis, Hip
Interventions: FX006, Normal saline; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 32
States / cities: Phoenix, Arizona • Tucson, Arizona • Canoga Park, California + 27 more

Conditions: Anticholinergics Toxicity
Interventions: Physostigmine, Lorazepam; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years to 17 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Acute Pain, Pain, Postoperative, Colorectal Surgery
Interventions: Placebo, Ketamine, Acetaminophen, Opioid, Alvimopan; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Invasive Bladder Cancer
Interventions: HIPEC; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 45 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
Interventions: JNJ-64179375 0.3 mg/kg, JNJ-64179375 0.6 mg/kg, JNJ-64179375 1.2 mg/kg, JNJ-64179375 (Dose to be Determined), JNJ-64179375 A mg/kg, JNJ-64179375 B mg/kg, JNJ-64179375 C mg/kg, JNJ-64179375 D mg/kg, Placebo JNJ-64179375, Apixaban placebo, Apixaban 2.5 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 50 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Phoenix, Arizona • Torrance, California • Englewood, Colorado + 4 more

Conditions: Healthy
Interventions: ketorolac, placebo, remifentanil, Capsaicin; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Search by objective public record fields.

Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation

Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit

Joint Injections for Osteoarthritic Knee Pain

Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants

TEAPOT Study Multisite

Intravenous Sub-dissociative Dose Ketamine Injection Versus Infusion for Analgesia in the Emergency Department

Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers

Recombinant CMV gB Vaccine in Postpartum Women

Greater Occipital Nerve Block for Migraine Prophylaxis

A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa

Trial of Topical Verapamil in Chronic Rhinosinusitis With Nasal Polyps

Pain Management After Total Shoulder Arthroplasty

Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

Liver Glycogen and Hypoglycemia in Humans

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome

Ketamine in Colorectal Surgery

HIPEC After Radical Cystectomy for High Risk Bladder Cancer

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

Effect of Spinal Ketorolac After Acute Opioid Exposure